Evidence map›Paper›PMID 19804414›Full record

ReviewThe FEBS journal2009

LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles.

Zhenyu Yue

Open access · greenAbstract readReview
In one paragraph

Review in The FEBS journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.Movement disorders : official journal of the Movement Disorder Society · 2013
    Review
  5. Review
  6. Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.Movement disorders : official journal of the Movement Disorder Society · 2011
    Review
  7. Article
  8. Article
  9. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.BioEssays : news and reviews in molecular, cellular and developmental biology · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Zhenyu YueDepartment of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA. zhenyu.yue@mssm.edu
Icahn School of Medicine at Mount Sinai · US

Funding

Using BAC-transgenic and Proteomic Approach to Study LRRK2 Biology and PathologyR01NS060809 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI YUE, ZHENYU · 2008 to 2017
$4.2M
LRRK2 Proteomics: Kinase/GTPase Hypothesis and Interaction PartnersR21NS055683 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI YUE, ZHENYU · 2006 to 2007
$414k
Exploration of motor deficits and cognitive impairments in LRRK2 transgenic miceR21NS061152 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI YUE, ZHENYU, ZHOU, QIANG · 2008 to 2009
$408k
NINDS NIH HHS NS060809NINDS NIH HHS NS061152NINDS NIH HHS R01 NS060809NINDS NIH HHS R21 NS055683NINDS NIH HHS R21 NS061152PHS HHS RNS055683A
6 · The paper itself

Abstract

The recent discovery of the genetic causes for Parkinson's disease (PD) is fruitful; however, the continuing revelation of PD-related genes is rapidly outpacing the functional characterization of the gene products. Although the discovery of multiple PD-related genes places PD as one of the most complex multigenetic diseases of the brain, it will undoubtedly facilitate the unfolding of a central pathogenic pathway and an understanding of the etiology of PD. Recent findings of pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) (PARK8) that are linked to the most common familial forms and some sporadic forms of PD provide a unique opportunity to gain insight into the pathogenesis of PD. Despite rapid growth in biochemical, structural and in vitro cell culture studies of LRRK2, the in vivo characterizations of LRRK2 function generally fall short and are largely limited to invertebrates. The investigation of LRRK2 or homologs of LRRK2 in nonmammalian models provides important clues with respect to the cellular functions of LRRK2, but an elucidation of the physiology and pathophysiology of LRRK2 relevant to PD would still depend on mammalian models established by multiple genetic approaches, followed by rigorous examination of the models for pathological process. This minireview summarizes previous studies of genes for ROCO and LRRK2 homologs in slime mold, nematode worms and fruit flies. It also discusses the results obtained from available mouse models of LRRK2 that begin to provide information for understanding LRRK2-mediated pathogenesis in PD.

Indexed as

AnimalsDrosophilaHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationMyxomycetesParkinson DiseaseProtein Serine-Threonine KinasesSignal TransductionLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanLrrk2 protein, mouseProtein Serine-Threonine Kinases

Identifiers

PMID19804414
PMCPMC2827245
OpenAlexW2051491274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.